AstraZeneca (AZN): H1 2026 results, my verdict

2026-07-27 · By Lubin Danilo, founder of Lubin Investment

AZN: see the full analysis on Lubin Investment

AstraZeneca reported first half revenue of $30.7 billion on July 27, 2026, up 9%, driven by oncology growing 18%, with core earnings per share up 11%. My quality filter validates 8 out of 10 criteria, but my price model judges the stock overvalued by more than 50% after its recent strong run.

A first half powered by oncology, despite the loss of a key patent

AstraZeneca reported its first half and second quarter 2026 results on July 27, 2026: total revenue of $30.672 billion, up 9% at reported exchange rates (6% at constant exchange rates), and core earnings per share (a company-defined measure that strips out certain one-off accounting items to give a cleaner picture of recurring profitability) up 11% to $5.21. The quarter beat analyst consensus on reported earnings per share ($2.63 versus $2.55 expected, a +3.1% surprise), and the stock reacted positively the same day, in a broadly higher US market.

The real engine of the half is oncology: it now accounts for 46% of group revenue, at $14.124 billion, up 18% year over year. Two treatments drive most of that growth. Enhertu, a treatment for several forms of breast cancer developed with Japan's Daiichi Sankyo, grew 31% on the share booked by AstraZeneca, driven by growing adoption across new indications. Tagrisso, the reference treatment for a form of lung cancer tied to a specific genetic mutation (EGFR), also kept climbing. The Rare Disease division was not left behind, at $4.911 billion, up 13%.

The cloud in this picture: Farxiga, a diabetes and heart failure treatment that long ranked among the group's best sellers, lost its US patent. In practice, competitors can now sell much cheaper generic copies, and a share of US prescribers and insurers mechanically shifts toward those generics. On top of that, China adds a drag, where a state bulk-buying scheme (volume-based procurement, which negotiates very low prices in exchange for guaranteed large volumes) weighs on the prices of several portfolio drugs. These two headwinds explain why overall growth comes in at 9% at constant currency rather than the double digit pace oncology alone would suggest.

Why my quality filter validates 8 out of 10 criteria

My standard model confirms a profitable, operationally solid company: a 17.4% net margin, a 14.8% free cash flow margin (nearly 15 cents of cash left over for every revenue dollar, after both expenses AND investments), and margins expanding over time (revenue growing faster than costs). Return on invested capital (cash ROCE, a measure of how efficiently the company turns reinvested capital into real profit) comes in at 15.0%, above the 15% threshold my model requires, and shares outstanding have stayed essentially flat over 5 years (+0.04% a year), a sign AstraZeneca is not diluting shareholders to fund its growth.

The two points missing for a perfect score are growth related: revenue grows 9.8% a year on average over 5 years, just under the 10% a year bar my model requires, and free cash flow per share grows only 6.6% a year over the same period, a decent rate but far from the standards of the best stocks in my screener. This gap between sales growth near 10% and cash-per-share growth of only 6.6% tells a specific story: part of the extra revenue flows into costly clinical research (phase 3 trials, which often cost several hundred million dollars per molecule) needed to keep the pipeline of new drugs that must one day replace Farxiga and the other patents that will expire in turn.

The mechanic to understand: the race between innovation and the patent cliff

What is happening to Farxiga this year is not an isolated accident, it is how the pharmaceutical industry normally works: a patent protects a molecule for a fixed period (generally around 20 years from filing), after which any manufacturer can produce and sell a generic copy, almost always at a much lower price. Investors call this moment the patent cliff, because sales of the original drug often fall 70 to 90% within a few quarters once generics are available, particularly in the US market where generic substitution at the pharmacy counter is fast and nearly automatic.

The only durable defense against a patent cliff is always having one or more growth engines already on the market or nearing the end of development by the time the old drug enters the public domain. That is exactly what this half shows: oncology's 18% growth (Enhertu, Tagrisso) largely offsets Farxiga's erosion, so total revenue still grows 9%. That is also why management reaffirmed its target of $80 billion in annual revenue by 2030 (versus roughly $58.7 billion in fiscal 2025): that figure assumes the pace of new treatment launches stays at least as fast as the pace at which old patents expire. The reverse risk exists too: if the pipeline slows or a phase 3 trial fails on a molecule deemed strategic, the next cliff (other portfolio patents will come due in the coming years) would no longer be offset as easily.

The price: a stock near the top of its own valuation history

The P/FCF (the share price divided by free cash flow generated per share over the trailing twelve months, a way to measure how many years of current cash it would take to "pay back" the price paid) comes out at 30.6 times. Taken alone, this figure looks like the upper end of the pharma sector average (the median across the 32 peers tracked by my screener is 21.4 times), but the real signal comes from the stock's own history: this 30.6 times P/FCF sits at the 85th percentile of AstraZeneca's past five years of trading, in other words the stock has been more expensive, on its own recent history, only about 15% of the time. The market is therefore paying near the highest valuation level AstraZeneca has commanded in the past five years.

My reasonable buy price model (which projects the company's actual free cash flow per share trajectory to compute what the stock should be worth today to deliver a fair future return) targets only $80.84, against a $169.64 share price at the time of publication. That is a 52.3% premium over what the past five years of cash generation would strictly justify (free cash flow rising from $6.57 billion in 2023 to $8.67 billion in 2025, real progress but not matching the pace of the stock's price appreciation). The market here is betting on something beyond the recent track record: confirmation, quarter after quarter, that the oncology pipeline can keep growing near 20% a year long enough to fund the 2030 target of $80 billion, a future trajectory far more favorable than the one of the past five years.

How I read it

AstraZeneca is a genuinely quality pharmaceutical company: profitable, lightly indebted relative to its cash (net debt repayable in 2.70 years of free cash flow, well under the 3 year threshold my model uses as a prudence benchmark), with an oncology growth engine that proved this half it can offset a real patent loss. The quarterly dividend was in fact raised, a sign of management's confidence in the cash trajectory ahead, for a current yield of about 1.9% with a 47.7% payout ratio of earnings, a comfortable cushion that does not endanger research spending.

What would change my mind: a slowdown in Enhertu or Tagrisso growth in coming quarters, at a time when Farxiga keeps eroding, would break the equation that worked this half and make the current premium much harder to justify. Conversely, if oncology's 18% growth pace holds for several consecutive quarters (not just this one), my model's cash trajectory would mechanically improve, narrowing the gap between the target price and the current one. I am watching Enhertu's quarterly growth in particular, which must now do most of the work offsetting Farxiga's erosion. You can find the full breakdown on the AstraZeneca analysis page, understand when paying a high P/FCF can be justified in my article on high P/FCF, why controlled debt is not a problem in my article on debt in my method, and my full methodology.

H1/Q2 2026 results (July 27): revenue of $30.672B (+9%, +6% at constant currency), core earnings per share of $5.21 (+11%). Reported quarterly EPS of $2.63, above the $2.55 consensus.
Oncology the engine of the half: $14.124B (46% of revenue, +18%), driven by Enhertu (+31%) and Tagrisso. Rare Disease at $4.911B (+13%). Farxiga slowed by its US patent loss, China hurt by state bulk-buying.
Quality score 8 out of 10: net margin 17.4%, FCF margin 14.8%, cash ROCE 15.0%, net debt repayable in 2.70 years, virtually no dilution. Missing: sales growth of 9.8%/year (just under my 10% threshold) and FCF per share up only 6.6%/year, part of the extra revenue funding clinical research for the pipeline's replacement drugs.
Price: P/FCF of 30.6 times, at the 85th percentile of the stock's past 5 years (near its historical high). My buy price model targets only $80.84 against a $169.64 share price, a 52.3% premium betting on the current oncology growth pace continuing.
Verdict: genuine pharma quality with a growth engine (oncology) that proved itself this half against a real patent loss, but a price that leaves no more room for error. I am watching Enhertu's quarterly growth before settling the price question.

FAQ

Why did AstraZeneca's revenue grow only 9% when oncology is up 18%?

Because Farxiga, a former diabetes and heart failure bestseller, lost its US patent and is seeing sales eaten into by much cheaper generic copies, while China imposes bulk purchasing at slashed prices on part of the portfolio. These two drags offset part of oncology's strong growth.

What is a 'patent cliff' in pharma?

The moment a drug loses the legal protection of its patent (generally after 20 years) and competitors can sell much cheaper generic copies, which often causes the original drug's sales to fall 70 to 90% within a few quarters, particularly in the US where generic substitution at the pharmacy is nearly automatic.

Why is AstraZeneca's quality score only 8 out of 10?

My filter judges a 5 year trajectory where revenue growth (9.8%/year) stays just under my 10%/year threshold, and free cash flow per share grows only 6.6%/year, part of the extra revenue being reinvested in costly clinical research that must fund future growth engines.

Is AstraZeneca stock expensive after these results?

Its 30.6 times P/FCF sits at the 85th percentile of its own 5 year history, near its most expensive. My buy price model, based on the actual 5 year cash trajectory, targets only $80.84 against a $169.64 share price, a 52.3% premium betting on the current oncology growth continuing.

Should I buy AstraZeneca stock after these results?

The company shows genuine fundamental quality and an oncology growth engine that proved this half it can offset a real patent loss, but the current price already prices in much of that favorable scenario, with a premium of more than 50% per my model. This is not personalized investment advice: do your own research.

About the author

Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I find fundamental analysis fascinating, and it has delivered excellent results. For three years now, my performance has beaten the S&P 500. But analyzing every stock took too much time: sites with incomplete data, calculation methods and criteria never aligned with mine. And spotting the best stocks was just as time-consuming, even with my own well-defined checklist. So I put my software development background to work to build this software, base my investment strategy on its results, and share it with people who share the same passion as me. It judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).